Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

A patient died after receiving Pfizer Inc.’s drug for hemophilia, marking another setback for the company in the treatment of ...

Pfizer faces another year of revenue decline in 2026, as Covid and loss-of-exclusivity headwinds weigh on top line growth.

Let’s dive into details regarding each of the evaluated factors, but first, for quick context: With $143 Bil in market ...

Pfizer’s shares, after a year of modest growth, recently fell following a cautious outlook for 2026, emphasizing ongoing ...

Pfizer said on Tuesday the next few years will be bumpy, beginning with 2026, due to lower sales of its COVID vaccine and ...

Pfizer Is Still Struggling to Replace Its COVID Revenue. Here's What We Could See From the Pharmaceutical Giant in 2026. Keep your expectations in check.

Built into the 2026 guidance is a $1.5 billion decline in sales of its COVID products—from an estimated $6.5 billion this ...

A patient in an open label extension study of Pfizer’s hemophilia treatment Hympavzi has died, the company and several ...

A patient who was being treated with Pfizer's hemophilia drug, Hympavzi, as part of a long-term study died after experiencing ...

The New York Times once called John Lamattina, then Pfizer head of R&D, “Dr. Optimistic.” He’s not so optimistic now.

Amid profit forecast reductions, Pfizer is implementing a $7.7bn cost-cutting strategy, while investing into its ...